Treatment Outcomes in Patients with Advanced Fibrolamellar Hepatocellular Carcinoma Under Systemic Treatment: Analysis of Clinical Characteristics, Management, and Radiomics

References

• Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956;91:168–186. doi:10.1001/ARCHPEDI.1956.02060020170015
   PubMedGoogle Scholar
• Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182. doi:10.1111/HIS.13975
   PubMed Web of Science ®Google Scholar
• Pawlik T, Lafaro K. Fibrolamellar hepatocellular carcinoma: current clinical perspectives. J Hepatocell Carcinoma. 2015;2:157. doi:10.2147/JHC.S75153
   Google Scholar
• El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39:798–803. doi:10.1002/HEP.20096
   PubMed Web of Science ®Google Scholar
• Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014;343:1010–1014. doi:10.1126/SCIENCE.1249484
   PubMed Web of Science ®Google Scholar
• Glavas D, Bao QR, Scarpa M, et al. Treatment and prognosis of fibrolamellar hepatocellular carcinoma: a systematic review of the recent literature and meta-analysis. J Gastrointest Surg. 2023;27:705–715. doi:10.1007/S11605-023-05621-Z
   PubMed Web of Science ®Google Scholar
• Ang CS, Kelley RK, Choti MA, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013;6:3.
   PubMedGoogle Scholar
• Kassahun WT. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol. 2016;14:151. doi:10.1186/S12957-016-0903-8
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Shama M, Sahin IH, et al. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology. 2013;85:197–203. doi:10.1159/000354698
   PubMed Web of Science ®Google Scholar
• El Dika I, Mayer RJ, Venook AP, et al. A multicenter randomized three-arm phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in patients with unresectable fibrolamellar carcinoma. Oncologist. 2020;25:925–e1603. doi:10.1634/THEONCOLOGIST.2020-0367
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Mayer R, Venook AP, et al. Phase II multicenter, open-label study of oral ENMD-2076 for the treatment of patients with advanced fibrolamellar carcinoma. Oncologist. 2020;25:e1837–45. doi:10.1634/THEONCOLOGIST.2020-0093
   PubMed Web of Science ®Google Scholar
• Chen KY, Popovic A, Hsiehchen D, et al. Clinical outcomes in fibrolamellar hepatocellular carcinoma treated with immune checkpoint inhibitors. Cancers. 2022;14:5347. doi:10.3390/CANCERS14215347/S1
   PubMedGoogle Scholar
• Polychronidis G, Murtha-Lemekhova A, Fuchs J, Hoffmann K, Karathanasi E. A multidisciplinary approach to the management of fibrolamellar carcinoma: current perspectives and future prospects. Onco Targets Ther. 2022;15:1095–1103. doi:10.2147/OTT.S296127
   PubMed Web of Science ®Google Scholar
• Fonseca GM, Varella AD, Coelho FF, Abe ES, Dumarco RB, Herman P. Downstaging and resection after neoadjuvant therapy for fibrolamellar hepatocellular carcinoma. World J Gastrointest Surg. 2014;6:107. doi:10.4240/WJGS.V6.I6.107
   PubMedGoogle Scholar
• Lamarca A, Frizziero M, Fulton A, et al. Fibrolamellar carcinoma: challenging the challenge. Eur J Cancer. 2020;137:144–147. doi:10.1016/J.EJCA.2020.06.035
   PubMed Web of Science ®Google Scholar
• Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003;21:421–427. PMID: 12560429. doi:10.1200/JCO.2003.10.103
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563–577. PMID: 26579733. doi:10.1148/RADIOL.2015151169
   PubMed Web of Science ®Google Scholar
• Koçak B, Durmaz EŞ, Ateş E, Kılıçkesmez Ö. Radiomics with artificial intelligence: a practical guide for beginners. Diagnostic Interv Radiol. 2019;25:485. PMID: 31650960. doi:10.5152/DIR.2019.19321
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104–7. doi:10.1158/0008-5472.CAN-17-0339
   PubMed Web of Science ®Google Scholar
• McInnes L, Healy J, Saul N, Großberger L. UMAP: uniform manifold approximation and projection. J Open Source Softw. 2018;3:862. doi:10.21105/JOSS.00861
   Google Scholar
• Chen T, Guestrin C. XGBoost: a scalable tree boosting system. Proc ACM SIGKDD Int Conf Knowl Discov Data Min. 2016;785–794. doi:10.1145/2939672.2939785
   Google Scholar
• Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg. 2012;215:820–830. doi:10.1016/J.JAMCOLLSURG.2012.08.001
   PubMed Web of Science ®Google Scholar
• Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106:1331. doi:10.1002/CNCR.21703
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Tella SH, Kommalapati A, et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol. 2019;10:554–561. doi:10.21037/JGO.2019.01.35
   PubMed Web of Science ®Google Scholar
• Abdelhamed W, El-Kassas M. Fibrolamellar hepatocellular carcinoma: a rare but unpleasant event. World J Gastrointest Oncol. 2022;14:1103–1114. doi:10.4251/wjgo.v14.i6.1103
   PubMed Web of Science ®Google Scholar
• Chagas AL, Kikuchi L, Herman P, et al. Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases. Clinics. 2015;70:207–213. doi:10.6061/clinics/2015(03)10
   PubMed Web of Science ®Google Scholar
• Herman P, Chagas AL, Perini MV, et al. Surgical treatment of fibrolamellar hepatocellular carcinoma: an underestimated malignant tumor? Hepatobiliary Pancreat Dis Int. 2014;13:618–621. doi:10.1016/S1499-3872(14)60294-0
   PubMed Web of Science ®Google Scholar
• Yamashita S, Vauthey JN, Kaseb AO, et al. Prognosis of fibrolamellar carcinoma compared to non-cirrhotic conventional hepatocellular carcinoma. J Gastrointest Surg. 2016;20:1725–1731. doi:10.1007/S11605-016-3216-X
   PubMed Web of Science ®Google Scholar
• Polychronidis G, Feng J, Murtha-Lemekhova A, Heger U, Mehrabi A, Hoffmann K. Factors influencing overall survival for patients with fibrolamellar hepatocellular carcinoma: analysis of the surveillance, epidemiology, and end results database. Int J Gen Med. 2022;15:393–406. doi:10.2147/IJGM.S338066
   PubMed Web of Science ®Google Scholar
• Maniaci V, Davidson BR, Rolles K, et al. Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. Eur J Surg Oncol. 2009;35:617–621. doi:10.1016/J.EJSO.2008.12.009
   PubMed Web of Science ®Google Scholar
• Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009;10:794–800. doi:10.1016/S1470-2045(09)70171-8
   PubMed Web of Science ®Google Scholar
• Graham RP, Yeh MM, Lam-Himlin D, et al. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Mod Pathol. 2018;31:141–149. doi:10.1038/MODPATHOL.2017.103
   PubMed Web of Science ®Google Scholar
• Kim YJ, Rhee H, Yoo JE, et al. Tumour epithelial and stromal characteristics of hepatocellular carcinomas with abundant fibrous stroma: fibrolamellar versus scirrhous hepatocellular carcinoma. Histopathology. 2017;71:217–226. doi:10.1111/HIS.13219
   PubMed Web of Science ®Google Scholar
• Cornella H, Alsinet C, Sayols S, et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology. 2015;148:806–818.e10. doi:10.1053/J.GASTRO.2014.12.028
   PubMed Web of Science ®Google Scholar
• Yang Y, Fan W, Gu T, et al. Radiomic features of multi-ROI and Multi-Phase MRI for the prediction of microvascular invasion in solitary hepatocellular carcinoma. Front Oncol. 2021;11:756216. doi:10.3389/fonc.2021.756216
   PubMedGoogle Scholar
• Yao W, Yang S, Ge Y, et al. Computed tomography radiomics-based prediction of microvascular invasion in hepatocellular carcinoma. Front Med. 2022;9. doi:10.3389/FMED.2022.819670
   Web of Science ®Google Scholar
• Ma X, Wei J, Gu D, et al. Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT. Eur Radiol. 2019;29:3595–3605. doi:10.1007/s00330-018-5985-y
   PubMed Web of Science ®Google Scholar
• Tarsitano A, Ricotta F, Cercenelli L, et al. Pretreatment tumor volume and tumor sphericity as prognostic factors in patients with oral cavity squamous cell carcinoma. J Craniomaxillofac Surg. 2019;47:510–515. doi:10.1016/J.JCMS.2018.12.019
   PubMed Web of Science ®Google Scholar
• Davey A, van Herk M, Faivre-Finn C, Mistry H, McWilliam A. Is tumour sphericity an important prognostic factor in patients with lung cancer? Radiother Oncol. 2020;143:73–80. doi:10.1016/J.RADONC.2019.08.003
   PubMed Web of Science ®Google Scholar
• Li W, Newitt DC, Yun B, et al. Tumor sphericity predicts response in neoadjuvant chemotherapy for invasive breast cancer. Tomography. 2020;6:216. doi:10.18383/J.TOM.2020.00016
   PubMed Web of Science ®Google Scholar
• Rajpurkar P, Lungren MP. The current and future state of AI interpretation of medical images. N Engl J Med. 2023;388:1981–1990. doi:10.1056/NEJMRA2301725
   PubMed Web of Science ®Google Scholar
• Da Fonseca L, Uratani L, Soares G, et al. Early variation of inflammatory indexes refines prognostic prediction in patients with hepatocellular carcinoma under systemic treatment. Mol Clin Oncol. 2023;18(4). doi:10.3892/MCO.2023.2625
   PubMed Web of Science ®Google Scholar